The bicyclam AMD3100 story - PubMed (original) (raw)
Review
doi: 10.1038/nrd1134.
Affiliations
- PMID: 12815382
- DOI: 10.1038/nrd1134
Review
The bicyclam AMD3100 story
Erik De Clercq. Nat Rev Drug Discov. 2003 Jul.
Abstract
The discovery and development of the bicyclam AMD3100--a chemokine receptor antagonist--has highlighted the therapeutic potential of such compounds in HIV infection, inflammatory diseases, cancer and stem-cell mobilization. Here, I describe the development process of AMD3100, which began about 15 years ago with the isolation of an impurity, and the basis for the clinical application of AMD3100 and its congeners.
Similar articles
- Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.
De Clercq E. De Clercq E. Mol Pharmacol. 2000 May;57(5):833-9. Mol Pharmacol. 2000. PMID: 10779364 Review. - The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).
De Clercq E. De Clercq E. Biochem Pharmacol. 2009 Jun 1;77(11):1655-64. doi: 10.1016/j.bcp.2008.12.014. Epub 2008 Dec 31. Biochem Pharmacol. 2009. PMID: 19161986 Review. - The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis.
Blanco J, Barretina J, Henson G, Bridger G, De Clercq E, Clotet B, Esté JA. Blanco J, et al. Antimicrob Agents Chemother. 2000 Jan;44(1):51-6. doi: 10.1128/AAC.44.1.51-56.2000. Antimicrob Agents Chemother. 2000. PMID: 10602722 Free PMC article. - Potential clinical applications of the CXCR4 antagonist bicyclam AMD3100.
De Clercq E. De Clercq E. Mini Rev Med Chem. 2005 Sep;5(9):805-24. doi: 10.2174/1389557054867075. Mini Rev Med Chem. 2005. PMID: 16178723 Review. - Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.
Hatse S, Princen K, Gerlach LO, Bridger G, Henson G, De Clercq E, Schwartz TW, Schols D. Hatse S, et al. Mol Pharmacol. 2001 Jul;60(1):164-73. doi: 10.1124/mol.60.1.164. Mol Pharmacol. 2001. PMID: 11408611
Cited by
- Potential protective association of the AA genotype and a allele of CXCR4 rs2228014 polymorphism with COVID-19 severity in adult egyptians.
Korayem OH, Ahmed AE, Meabed MH, Magdy DM, Abdelghany WM. Korayem OH, et al. BMC Infect Dis. 2024 Oct 15;24(1):1158. doi: 10.1186/s12879-024-09602-8. BMC Infect Dis. 2024. PMID: 39407172 Free PMC article. - Rigid Macrocycle Metal Complexes as CXCR4 Chemokine Receptor Antagonists: Influence of Ring Size.
Renard I, D'huys T, Burke BP, Ajoleza T, Cain AN, Funwie NL, Khan A, Maples DL, Maples RD, Matz DL, McRobbie G, Ullom R, Prior TJ, Linder DP, Van Loy T, Hubin TJ, Schols D, Archibald SJ. Renard I, et al. Pharmaceutics. 2024 Jul 28;16(8):1000. doi: 10.3390/pharmaceutics16081000. Pharmaceutics. 2024. PMID: 39204345 Free PMC article. - The story of clobenpropit and CXCR4: can be an effective drug in cancer and autoimmune diseases?
Abbasifard M, Bagherzadeh K, Khorramdelazad H. Abbasifard M, et al. Front Pharmacol. 2024 Jul 12;15:1410104. doi: 10.3389/fphar.2024.1410104. eCollection 2024. Front Pharmacol. 2024. PMID: 39070795 Free PMC article. Review. - A Cyclam Salt as an Antifungal Agent: Interference with Candida spp. and Cryptococcus neoformans Mechanisms of Virulence.
Cerqueira F, Medeiros R, Lopes I, Campos C, Ferraz MP, Silva F, Alves LG, Pinto E. Cerqueira F, et al. Antibiotics (Basel). 2024 Feb 28;13(3):222. doi: 10.3390/antibiotics13030222. Antibiotics (Basel). 2024. PMID: 38534657 Free PMC article. - Crosstalk between purinergic receptor P2Y11 and chemokine receptor CXCR7 is regulated by CXCR4 in human macrophages.
Klaver D, Gander H, Frena B, Amato M, Thurnher M. Klaver D, et al. Cell Mol Life Sci. 2024 Mar 13;81(1):132. doi: 10.1007/s00018-024-05158-7. Cell Mol Life Sci. 2024. PMID: 38472446 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical